LAUSR

https://ejgo.org It is well recognized that approximately 20% of ovarian cancer cases can be attributed to pathogenic variants in BRCA1/2 [1,2]. Therefore, the majority of ovarian cancer cases must be associated with other genetic or epidemiologic risk factors. Silencing of tumor suppressor genes including BRCA1/2 by promoter methylation has been shown to be associated with early onset ovarian cancer [3] and breast cancer [4]. Testing for BRCA1 methylation in the blood may be a feasible strategy to identify those who are at risk for developing ovarian cancer, even in the absence of a mutation in BRCA1/2. Since there is still no effective screening test for ovarian cancer, there is a need for novel strategies to identify those at increased risk for this malignancy, in addition to those with a hereditary predisposition attributed to a germline mutation in BRCA1/2.